One light removes what is inflaming your glands. The other works inside the cells that produce your tear film's oil. We use both.

Two treatments, each doing a job the other cannot.

IPL

LLLT

633 nm

400 nm 590 nm 1200 nm

The two are not interchangeable, because they act on different targets. IPL works on the environment around the gland: the abnormal vessels, the inflammatory load, the demodex. LLLT works on the gland cells themselves, on their metabolism and their capacity to secrete. Choosing one means accepting whichever half of the problem it does not reach.

Meibomian gland disease is not one problem. It is four, running at the same time, each one feeding the next. This is why a course of treatment can leave you feeling it nearly worked.

• Inflamed, abnormal vessels along the lid margin Telangiectatic vessels sitting millimetres from your cornea, delivering inflammatory mediators directly onto the ocular surface and keeping the whole cycle running. Closed by IPL
• Demodex and microbial load on the lash line Mites and the bacteria they carry, generating their own inflammation at the base of the lashes and blocking gland openings. Reduced by IPL
• Meibum thickened to the point that it cannot flow Oil that should have the consistency of olive oil behaving more like toothpaste, sitting hard inside the ducts. Softened by both, cleared by expression
• Gland cells that have stopped producing properly After months or years of obstruction and inflammation, the secretory cells themselves are underperforming. This is a functional problem, not a plumbing one, and heat does not fix it. Targeted by LLLT

addressedpartly addressednot addressed

Now leave any one of those out and follow it through.

Settle the inflammation, clear the blockage, but leave your gland cells still struggling, and the cause has been removed while the gland remains unable to do its job. Oil production stays low, your tear film stays unstable, and you come away saying it helped a bit.

Work on the gland cells but leave the inflamed vessels sitting on your lid margin, and production restarts into an environment that will obstruct and inflame it all over again within months.

Do both and skip the clearing, and the softened oil simply stays where it was and hardens again.

There is no version of this where doing part of it is as good as doing all of it. That is the whole case for combining, and it has nothing to do with one machine being better than another. The disease has four moving parts, and your session should not end with any of them untouched.

This is where combined light therapy is at its most useful, and where it is most often missed.

Between 30 and 50 percent of people with rosacea have ocular involvement, and meibomian gland dysfunction is the most common ocular sign. A great many are treated for their skin for years before anyone examines their lid margins, and arrive convinced their eyes are a separate and unrelated problem.

They are the same disease. Rosacea is a disorder of abnormal, inflamed blood vessels, and the vessels along your lid margin behave exactly as the ones across your cheeks do. That is why treatment aimed at one tends to help the other.

• IPL was developed for vascular skin lesions in the first place. In published series it improved facial erythema by around 46 percent and telangiectasia by around 55 percent, with other work reporting substantial clearance of facial rosacea and a marked reduction in flushing.
• In rosacea associated meibomian gland dysfunction specifically, a course of four treatments at three week intervals improved lid parameters and ocular symptoms, and those improvements held at long term follow up.
• Rosacea carries a higher demodex burden on the lash line, and demodex drives its own inflammatory cycle at the lid margin. IPL reduces that load.
• LLLT adds an anti inflammatory effect at the cellular level, downregulating interleukin 1 beta and tumour necrosis factor alpha within the eyelid tissue, without adding any further vascular or thermal load to skin that is already reactive.

If that is you, it means one course of treatment working on the vessels across your face, the vessels on your lid margins, the demodex population and your gland cells at the same time. Very little else in dry eye care does more than one of those at once.

The order matters. Each step prepares your eyelids for the next one, which is why the appointment takes the time it does.

1. Full dry eye assessmentMeibography, tear film stability, lipid layer and a validated symptom score, recorded before anything is switched on, so there is something to measure against later.
2. Eye protection in placeCorneal shields under the lids, or adhesive metal shields over closed eyes, depending on where treatment is being applied.
3. IPL to the treatment area and lid marginEnergy set against your Fitzpatrick skin type, and reset at each visit as the inflammatory vessels recede.
4. LLLT across both lidsEven, comfortable warming that reaches the full length of the upper and lower glands and softens what the IPL has begun to liquefy.
5. Meibomian gland expression, all four lidsAutoclaved steel paddles, applying measured force along the lid. This is the step that actually clears the softened oil out.
6. Reassessment and planWhat the glands did under expression informs the settings and spacing for next time.

Forty minutes, delivered by an optometrist from start to finish.

Most people describe the IPL as a series of brief, warm flashes against the skin, and the LLLT as little more than resting under a warm mask. You can drive yourself home afterwards and go back to work the same day.

Pairing light with an LLLT mask is not unusual in itself. Some packages offered elsewhere do exactly that, using a polychromatic light source marketed as OPE together with a light therapy mask, delivered in a short and fixed appointment.

So the question is not whether the therapies are combined. It is what is being combined, where it is applied, and what happens around it.

• The light itself. OptiLight is the only device of its kind with FDA authorisation for dry eye. Other IPL systems, such as OPE, may hold CE marking in Europe but do not have FDA authorisation for dry eye. As OPE uses a different emission technology, the trial evidence behind OptiLight’s authorisation does not carry across to it.
• Where it is applied. We treat the upper and lower lids and deliver light at the lid margin behind eye protection. Protocols confined to the cheek and below the eye leave the lid that carries the greater number of glands untreated.
• What follows the light. Every session here ends with expression of all four lids. Light that softens meibum without anyone clearing it afterwards leaves the blockage where it was.
• Who is holding the handpiece. An optometrist, for the whole session, not a technician working through a set protocol on a timer.
• Whether anyone can tell it worked. Baseline scans repeated through the course, so improvement is demonstrated rather than assumed.

Two clinics can both describe what they offer as combined light therapy for dry eye and be doing substantially different things. The device, the lids, the clearing step and the measurement are what separate them.